Page last updated: 2024-11-04

mecamylamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Mecamylamine is a non-competitive nicotinic acetylcholine receptor antagonist. It acts primarily by blocking the ganglionic transmission of nerve impulses. It was originally developed for the treatment of hypertension, but its use in this indication has declined due to the availability of safer and more effective alternatives. Currently, mecamylamine is primarily used in research settings to study the role of nicotinic acetylcholine receptors in various physiological and pathological processes. It is also being investigated as a potential therapeutic agent for conditions such as Alzheimer's disease, Parkinson's disease, and drug addiction. Mecamylamine is synthesized by reacting 2-chloro-4-methylaminopyridine with methylamine.'

Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID4032
CHEMBL ID267936
CHEBI ID6706
SCHEMBL ID34252
MeSH IDM0013160

Synonyms (90)

Synonym
DIVK1C_006832
n,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine
mecamine
mekamine
mecamylaminum [inn-latin]
mecamilamina [italian]
2-methylaminoisocamphane
2-methylamino-2,3,3-trimethylnorbornane
bicyclo(2.2.1)heptan-2-amine, n,2,3,3-tetramethyl-
3-beta-methylamino-2,2,3-trimethylbicyclo(2.2.1)heptane
3-methylaminoisokamfan [czech]
n,2,3,3-tetramethyl-2-norbornamine
mecamilamina [dcit]
n,2,3,3-tetramethyl-2-norcamphanamine
mecamylamine [inn:ban]
2-norbornanamine, n,2,3,3-tetramethyl-
einecs 200-476-1
n-methyl-2-isocamphanamine
revertina
3-methylaminoisocamphane
SPECTRUM_000304
PRESTWICK2_001111
LOPAC0_000841
SPECTRUM5_001616
PRESTWICK3_001111
AB00053764
60-40-2
versamine
C07511
mecamylamine
DB00657
BSPBIO_002292
BSPBIO_001242
BPBIO1_001367
NCGC00162272-02
KBIOGR_001814
KBIOSS_000784
KBIO2_003352
KBIO2_000784
KBIO3_001512
KBIO1_001776
KBIO2_005920
SPECPLUS_000736
PRESTWICK1_001111
PRESTWICK0_001111
SPBIO_003111
SPECTRUM3_000736
SPECTRUM4_001257
NCGC00162272-01
NCGC00015703-04
CHEMBL267936 ,
chebi:6706 ,
(-)methyl-(2,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amine
(+/-)methyl-(2,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amine
(+)methyl-(2,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amine
methyl-(2,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amine(mecamylamine)
bdbm50061565
methyl-(2,3,3-trimethyl-bicyclo[2.2.1]hept-2-yl)-amine
NCGC00015703-03
AKOS003662515
mecamylaminum
mecamilamina
3-methylaminoisokamfan
cas-60-40-2
dtxcid903240
tox21_110198
dtxsid0023240 ,
CCG-204924
NCGC00015703-02
gtpl3990
BRD-A20119038-003-01-1
SCHEMBL34252
NCGC00015703-06
tox21_110198_1
bicyclo[2.2.1]heptan-2-amine, n,2,3,3-tetramethyl-
inversine (salt/mix)
n,2,3,3-tetramethylbicyclo[2.2.1]heptan-2-amine #
3-.beta.-methylamino-2,2,3-trimethylbicyclo(2.2.1)heptane
HMS3604D12
AB00053764_03
SBI-0050817.P004
Q3332124
BRD-A20119038-001-01-5
SDCCGSBI-0050817.P005
NCGC00015703-12
EN300-267821
CS-0013657
HY-B1395A
mecamylaminum (inn-latin)
c02bb01

Research Excerpts

Overview

Mecamylamine is a nicotinic acetylcholine receptor (nAChR) antagonist that was recently used in a clinical trial to treat alcohol use disorder (AUD) in both smokers and non-smokers. Mecamyamine is reported in several animal studies to have paradoxical positive effects on cognition at ultra-low doses.

ExcerptReferenceRelevance
"Mecamylamine is a nicotinic acetylcholine receptor (nAChR) antagonist that was recently used in a clinical trial to treat alcohol use disorder (AUD) in both smokers and non-smokers. "( Tobacco use during a clinical trial of mecamylamine for alcohol dependence: Medication effects on smoking and associations with reductions in drinking.
McKee, SA; Petrakis, IL; Ralevski, E; Roberts, W; Verplaetse, TL, 2018
)
2.19
"Mecamylamine is a non-competitive nicotinic acetylcholine receptor (nAChR) antagonist that has been prescribed for hypertension and as an off-label smoking cessation aid. "( Discriminative stimulus effects of mecamylamine and nicotine in rhesus monkeys: Central and peripheral mechanisms.
Cunningham, CS; McMahon, LR; Moerke, MJ, 2019
)
2.23
"Dexmecamylamine (TC-5214) is a nicotinic channel modulator that was evaluated as a potential adjunct treatment to an antidepressant for patients with major depressive disorder. "( Clinical pharmacokinetics of the nicotinic channel modulator dexmecamylamine (TC-5214) in subjects with various degrees of renal impairment.
Alverlind, S; Barassin, S; Dalén, P; Eriksson, H; Li, Y; Toler, S; Tummala, R, 2014
)
1.26
"Mecamylamine is a non-competitive nicotinic antagonist which is reported in several animal studies to have paradoxical positive effects on cognition at ultra-low doses."( Effects of acute ultra-low dose mecamylamine on cognition in adult attention-deficit/hyperactivity disorder (ADHD).
Newhouse, PA; Potter, AS; Ryan, KK, 2009
)
1.36
"Mecamylamine is a nicotine antagonist under investigation in combination with nicotine replacement for smoking treatment."( Simultaneous quantification of nicotine, cotinine, trans-3'-hydroxycotinine, norcotinine and mecamylamine in human urine by liquid chromatography-tandem mass spectrometry.
Huestis, MA; Scheidweiler, KB; Shakleya, DM, 2012
)
2.04
"Mecamylamine is a well-described non specific antagonist of nicotinic acetylcholine receptors (nAChRs), used in therapy and in psychopharmacological studies. "( Evaluation in rats and primates of [11C]-mecamylamine, a potential nicotinic acetylcholine receptor radioligand for positron emission tomography.
Barré, L; Camsonne, R; Chazalviel, L; Debruyne, D; Dhilly, M; Kakiuchi, T; Sobrio, F; Tsukada, H, 2005
)
2.04
"Mecamylamine is an antihypertensive that acts via nicotinic antagonism and has been suggested as an aid in smoking cessation. "( Mecamylamine does not precipitate withdrawal in cigarette smokers.
Eissenberg, T; Griffiths, RR; Stitzer, ML, 1996
)
3.18
"Mecamylamine is a nicotine antagonist (that is it blocks the effect of nicotine). "( Mecamylamine (a nicotine antagonist) for smoking cessation.
Lancaster, T; Stead, LF, 2000
)
3.19

Effects

Mecamylamine (MCL) has been shown to extinguish nicotine dependence in animals and produce smoking cessation in some humans. The drug has little effect on the clearance of nicotine and is not expected to affect steady state levels during transdermal nicotine dosing.

ExcerptReferenceRelevance
"Mecamylamine (MCL) has been shown to extinguish nicotine dependence in rats and monkeys. "( Clinical evaluation of mecamylamine for withdrawal from nicotine dependence.
Rawson, RA; Tarver, AL; Tennant, FS, 1984
)
2.02
"Mecamylamine (MCL) has been shown to extinguish nicotine dependence in animals and produce smoking cessation in some humans. "( Withdrawal from nicotine dependence using mecamylamine: comparison of three-week and six-week dosage schedules.
Tarver, AL; Tennant, FS, 1984
)
1.97
"Mecamylamine has important interactions with dopaminergic (DA) systems."( Working memory performance and cholinergic effects in the ventral tegmental area and substantia nigra.
Auman, JT; Briggs, SJ; Christopher, NC; Levin, ED, 1994
)
1.01
"Mecamylamine has little effect on the clearance of nicotine and is not expected to affect steady-state levels during transdermal nicotine dosing. "( Nicotine-mecamylamine interactions.
Benowitz, NL; Jacob, P; Zevin, S, 2000
)
2.17

Actions

Mecamylamine failed to produce signs of precipitated withdrawal in either procedure. It is a cholinergic antagonist that blocks the phase-shifting effects of light on the circadian activity rhythm in the golden hamster.

ExcerptReferenceRelevance
"Mecamylamine failed to produce signs of precipitated withdrawal in either procedure."( Removal of continuous nicotine infusion produces somatic but not behavioral signs of withdrawal in mice.
Harris, LS; Kwilasz, AJ; Vann, RE, 2009
)
1.07
"Mecamylamine, because of its safety record in children with other disorders, was chosen for this first exploration. "( Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders.
Aman, MG; Anand, R; Arnold, LE; Bates, B; Farmer, C; Hollway, J; Hurt, E; Li, X; Ramadan, Y; Thompson, S; Williams, C, 2012
)
2.1
"Mecamylamine was chosen because it is a cholinergic antagonist that blocks the phase-shifting effects of light on the circadian activity rhythm in the golden hamster."( A cholinergic antagonist, mecamylamine, blocks light-induced fos immunoreactivity in specific regions of the hamster suprachiasmatic nucleus.
Kirby, JD; Takahashi, JS; Turek, FW; Zee, PC; Zhang, Y, 1993
)
1.31
"Mecamylamine tended to increase the cone-driven, but to decrease the rod-driven ON-component of the ONR."( Cholinergic effects on cat retina In vitro: changes in rod- and cone-driven b-wave and optic nerve response.
Jurklies, B; Kaelin-Lang, A; Niemeyer, G, 1996
)
1.02

Treatment

Mecamylamine pretreatment dramatically reduced light-induced Fos-lir in the SCN by 75%. Pretreatment also reduced lordotic behavior induced by bilateral intracerebroventricular (ICV) injection of the cholinesterase inhibitor, eserine.

ExcerptReferenceRelevance
"Mecamylamine treatment significantly attenuated expression of cocaine behavioral sensitization on both withdrawal days 7 and 14."( Time-dependent changes in nicotine behavioral responsivity during early withdrawal from chronic cocaine administration and attenuation of cocaine sensitization by mecamylamine.
Fowler, JC; Froeliger, B; Lee, TH; Szabo, ST, 2014
)
1.32
"Mecamylamine pretreatment and nicotine discontinuation rapidly recovered baseline performance."( Revisiting the effect of nicotine on interval timing.
Brackney, RJ; Daniels, CW; Garcia, R; Mazur, GJ; Sanabria, F; Watterson, E, 2015
)
1.14
"Mecamylamine pretreatment of nicotine-treated rats abrogated the increased periodontal bone loss and the LPS-induced TNF-alpha decrease, but had no significant effects on the levels of TGF-1beta and IL-10, or the stress hormone corticosterone."( Nicotinic acetylcholine receptor activation mediates nicotine-induced enhancement of experimental periodontitis.
Breivik, T; Gjermo, P; Gundersen, Y; Opstad, PK; von Hörsten, S, 2009
)
1.07
"Mecamylamine pretreatment of nicotine-treated rats abrogated the increased periodontal bone loss and the LPS-induced decrease in tumour necrosis factor-alpha, but had no significant effects on the levels of transforming growth factor-1beta and interleukin-10, or the stress hormone corticosterone."( Nicotinic acetylcholine receptor activation mediates nicotine-induced enhancement of experimental periodontitis.
Breivik, T; Gjermo, P; Gundersen, Y; Opstad, PK; von Hörsten, S, 2009
)
1.07
"Mecamylamine pretreatment did not significantly alter the effects of alcohol on SC amplitudes."( Interactions between mecamylamine and alcohol in Long-Evans rats: flash-evoked potentials, body temperature, behavior, and blood alcohol concentration.
Bauer, AM; Hetzler, BE, 2013
)
1.43
"Mecamylamine treatment caused a biphasic nociceptive response similar to that caused by isoflurane."( Isoflurane hyperalgesia is modulated by nicotinic inhibition.
Coates, KM; Flood, P; Gong, D; Sonner, JM, 2002
)
1.04
"Mecamylamine pretreatment attenuated the hyperactivity and sensitization produced by repeated, but not acute, ephedrine (10 mg/kg) injection."( Mecamylamine attenuates ephedrine-induced hyperactivity in rats.
Miller, DK; Segert, IL, 2005
)
2.49
"Mecamylamine pretreatment, but not hexamethonium, produced a loss of inhibitory control by nicotine suggesting a role for central nicotinic acetylcholine receptors."( Characterization of nicotine's ability to serve as a negative feature in a Pavlovian appetitive conditioning task in rats.
Bevins, RA; Palmatier, MI; Siebert, HL; Wilkinson, JL; Wiltgen, SM, 2006
)
1.06
"Mecamylamine treatment began 2 weeks before smoking cessation."( Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone.
Behm, FM; Levin, ED; Ripka, GV; Rose, JE; Stein, RM; Westman, EC, 1994
)
2.45
"Mecamylamine pretreatment dramatically reduced light-induced Fos-lir in the SCN by 75%."( A cholinergic antagonist, mecamylamine, blocks light-induced fos immunoreactivity in specific regions of the hamster suprachiasmatic nucleus.
Kirby, JD; Takahashi, JS; Turek, FW; Zee, PC; Zhang, Y, 1993
)
1.31
"Mecamylamine pretreatment reduced the morphine- and haloperidol-induced elevation of striatal HVA concentrations."( Effect of mecamylamine on the fate of dopamine in striatal and mesolimbic areas of rat brain; interaction with morphine and haloperidol.
Ahtee, L; Kaakkola, S, 1978
)
1.38
"Mecamylamine pretreatment prevented the prolactin response to nicotine only."( Partial characterization of a neurotransmitter pathway regulating the in vivo release of prolactin.
Flores, CM; Hornby, PJ; Hulihan-Giblin, BA; Kellar, KJ; Lumpkin, MD, 1992
)
1
"Mecamylamine pretreatment prevented the increase in alpha frequency caused by the 4 mg gum dose but not the 8 mg dose."( Mecamylamine reduces some EEG effects of nicotine chewing gum in humans.
Henningfield, JE; Herning, RI; Pickworth, WB, 1988
)
2.44
"Mecamylamine pretreatment also reduced lordotic behavior induced by bilateral intracerebroventricular (ICV) injection of the cholinesterase inhibitor, eserine (5 micrograms/cannula)."( Nicotinic cholinergic influences on sexual receptivity in female rats.
Clemens, LG; Weaver, DR, 1987
)
0.99
"Pretreatment with mecamylamine (nicotinic antagonist; 5 mm) abolished all the effects of ACh injected into the iNTS or the cNTS, whereas atropine (muscarinic antagonist; 5 mm) reduced only the effects of ACh injected into the cNTS."( Differential modulation of sympathetic and respiratory activities by cholinergic mechanisms in the nucleus of the solitary tract in rats.
Bassi, M; Colombari, DS; Colombari, E; Furuya, WI; Menani, JV; Zoccal, DB, 2014
)
0.73
"Pre-treatment with mecamylamine inhibited the rate-inhibiting properties of ethanol in the VTA, but not in the nAc."( Brain region specific modulation of ethanol-induced depression of GABAergic neurons in the brain reward system by the nicotine receptor antagonist mecamylamine.
Adermark, L; Burkhardt, JM; Söderpalm, B, 2014
)
0.92
"Pretreatment with mecamylamine completely blocked the nicotine-induced increase in the BOLD signal."( Acute nicotine administration increases BOLD fMRI signal in brain regions involved in reward signaling and compulsive drug intake in rats.
Alexander, JC; Bauzo-Rodriguez, R; Bruijnzeel, AW; Febo, M; Guerra, V; Hall, G; Igari, M; Klausner, R; Perez, PD; Zeng, H, 2014
)
0.73
"pretreatment with mecamylamine (50 microg), but not atropine (10 microg)."( Central choline suppresses plasma renin response to graded haemorrhage in rats.
Cansev, M; Hamurtekin, E; Ilcol, YO; Isbil-Buyukcoskun, N; Ozluk, K; Ulus, IH, 2008
)
0.67
"Pretreatment with mecamylamine (ganglionic blocker, 10 mg/kg i.v.) augmented the depressor response and abolished the tachycardic effect of intermedin/adrenomedullin-2 (3 nmol/kg)."( Vasodilator mechanism of intermedin/adrenomedullin-2 in anesthetized rats.
Abdelrahman, AM; Pang, CC, 2007
)
0.66
"Pretreatment with mecamylamine blocked the expression of conditioned hyperactivity only in EC and SC rats and attenuated sensitization in all three rearing groups."( Effects of mecamylamine on nicotine-induced conditioned hyperactivity and sensitization in differentially reared rats.
Cain, ME; Coolon, RA, 2009
)
1.07
"Pretreatment with mecamylamine, methyllycaconitine or alpha-bungarotoxin partially diminished the pressor and tachycardic response to melittin in the normotensive conscious rats whereas pretreatment with atropine sulfate had no effect."( Cardiovascular effect of peripheral injected melittin in normotensive conscious rats: Mediation of the central cholinergic system.
Aydin, C; Savci, V; Yalcin, M,
)
0.45
"Pretreatment with mecamylamine (0.5, 1, and 2 mg/kg, s.c.) dose-dependently attenuated the cue-induced reinstatement of lever responding."( Mecamylamine attenuates cue-induced reinstatement of nicotine-seeking behavior in rats.
Caggiula, AR; Liu, X; Nobuta, H; Pechnick, RN; Poland, RE; Sved, AF; Yee, SK, 2007
)
2.11
"Pretreatment with mecamylamine, hemicholinium-3, methyllycaconitine or alpha-bungarotoxin partially attenuated the pressor and bradicardia effect of elicited by melittin in the normotensive conscious rats whereas pretreatment with atropine had no effect."( The involvement of the central cholinergic system in the pressor and bradycardic effects of centrally administrated melittin in normotensive conscious rats.
Erturk, M; Yalcin, M, 2007
)
0.66
"Pre-treatment with mecamylamine (50 mug; i.c.v.) or hexamethonium (15 mg/kg; i.p.), but not atropine (10 mug; i.c.v.), prevented i.c.v."( Peripheral administration of CDP-choline, phosphocholine or choline increases plasma adrenaline and noradrenaline concentrations.
Cansev, M; Hamurtekin, E; Ilcol, YO; Ulus, IH; Yilmaz, MS, 2008
)
0.66
"Pretreatment with mecamylamine (0.5 mg/kg) prevented convulsions but had only a slight effect on the decreased motor activity."( Pharmacodynamic effects of nicotine and acetylcholine biosynthesis in mouse brain.
Nordberg, A; Sundwall, A, 1983
)
0.59
"Pretreatment with mecamylamine caused a decline in DNA synthesis by itself, but nevertheless prevented the effect of chlorpyrifos."( Developmental neurotoxicity of chlorpyrifos: cellular mechanisms.
Seidler, FJ; Slotkin, TA; Whitney, KD, 1995
)
0.61
"Pretreatment with mecamylamine (50 micrograms; i.c.v.), but not atropine (10 micrograms; i.c.v.), blocked both the pressor and vasopressin responses to i.c.v."( Central choline reverses hypotension caused by alpha-adrenoceptor or ganglion blockade in rats: the role of vasopressin.
Savci, V; Ulus, IH, 1996
)
0.62
"Pretreatment with mecamylamine completely blocked the THA-induced increase in NA and 5-HT turnover, but not in DA turnover, suggesting that the nACh-R system is involved in the THA-induced increase in brain NA and 5-HT turnover."( Nicotinic acetylcholine receptor (nACh-R) agonist-induced changes in brain monoamine turnover in mice.
Imoto, M; Ohno, T; Saito, K; Tani, Y; Tsuneyoshi, A, 1997
)
0.62
"Pre-treatment with mecamylamine (1 mg kg(-1)) prevented the expression of the locomotor stimulant effects of nicotine but pre-treatment with i.c.v."( Mecamylamine but not the alpha7 receptor antagonist alpha-bungarotoxin blocks sensitization to the locomotor stimulant effects of nicotine.
Kempsill, FE; Pratt, JA, 2000
)
2.07
"Pretreatment with mecamylamine lowered brain nicotine levels in adult mice, and in infant mice the nicotine levels in blood and heart were lowered as well."( Pharmacokinetics of nicotine in adult and infant mice.
Mansner, R; Mattila, MJ, 1977
)
0.58
"Pretreatment with mecamylamine prevented nicotine-induced tremor and antidiuresis."( Nicotine induced tremor and antidiuresis and brain nicotine levels in the rat.
Mansner, R; Mattila, MJ, 1975
)
0.58
"Pretreatment with mecamylamine (5.0 mg/kg i.v.) prevented the nicotine-induced changes in somatostatin level and binding in both brain areas."( Effects of acute nicotine and mecamylamine administration on somatostatin concentration and binding in the rat brain.
Arilla, E; Barrios, V; Colas, B; Rodriguez-Sanchez, MN, 1990
)
0.89
"Pretreatment with mecamylamine (2 mg kg-1, s.c.) was effective in attenuating the stimulatory effect of either nicotine or cytisine."( The importance of nucleus accumbens in nicotine-induced locomotor activity.
Fung, YK, 1990
)
0.6
"Pretreatment with mecamylamine (1.0 mg kg-1) counteracted the cigarette smoke induced changes in CA levels and turnover in all hypothalamic CA nerve terminal regions as well as the changes in serum levels of the pituitary hormones and corticosterone."( Mecamylamine pretreatment counteracts cigarette smoke induced changes in hypothalamic catecholamine neuron systems and in anterior pituitary function.
Andersson, K, 1985
)
2.04

Toxicity

ExcerptReferenceRelevance
" An additive toxic effect of atropine was suggested with its combinations with TMB4, mecamylamine, and diazepam, whereas no additive toxicity occurred with combinations involving hexamethonium or benactyzine (i."( Efficacy and toxicity of drug combinations in treatment of physostigmine toxicosis.
Klemm, WR, 1983
)
0.49
"The present study directly compared the antinociceptive and toxic effects of the neuronal nicotinic receptor agonist ABT-594 ((R)-5-(2-azetidinylmethoxy)-2-chloropyridine) with (-)-nicotine and (+)-epibatidine."( Analgesic and toxic effects of ABT-594 resemble epibatidine and nicotine in rats.
Boyce, S; Hill, RG; Rupniak, NMJ; Russell, MGN; Shepheard, SL; Webb, JK, 2000
)
0.31
" This study examines the hypothesis for the first time that the neonicotinoid insecticides and their imine metabolites and analogs display analgesic (antinociceptive) activity or adverse toxic effects associated with their action on binding to the alpha 4 beta 2 nicotinic acetylcholine receptor (AChR) subtype."( Analgesic and toxic effects of neonicotinoid insecticides in mice.
Casida, JE; Cowan, A; Tomizawa, M, 2001
)
0.31
" In addition to the stimulatory effects of both ethanol and nicotine on the mesolimbic reward pathway, nicotine's ability to counteract some of the adverse effects of ethanol (e."( Protective effects of nicotine on ethanol-induced toxicity in cultured cerebellar granule cells.
Al-Namaeh, M; Manaye, KF; Taylor, RE; Tizabi, Y, 2003
)
0.32
"We evaluated mechanisms contributing to the adverse effects of chlorpyrifos (CPF) on DNA synthesis, cell number and size, and cell signaling mediated by adenylyl cyclase (AC) in PC12 cells, a neuronotypic cell line that recapitulates the essential features of developing mammalian neurons."( Ameliorating the developmental neurotoxicity of chlorpyrifos: a mechanisms-based approach in PC12 cells.
MacKillop, EA; Ryde, IT; Seidler, FJ; Slotkin, TA, 2007
)
0.34
" Nicotine, which stimulates nicotinic acetylcholine receptors but also possesses a mixture of prooxidant/antioxidant activity, had adverse effects by itself but also protected undifferentiated cells from the actions of CPF and had mixed additive/protective effects on cell number in differentiating cells."( Ameliorating the developmental neurotoxicity of chlorpyrifos: a mechanisms-based approach in PC12 cells.
MacKillop, EA; Ryde, IT; Seidler, FJ; Slotkin, TA, 2007
)
0.34
"Our results show definitive contributions of cholinergic hyperstimulation, oxidative stress, and interference with AC signaling in the developmental neurotoxicity of CPF and point to the potential use of this information to design treatments to ameliorate these adverse effects."( Ameliorating the developmental neurotoxicity of chlorpyrifos: a mechanisms-based approach in PC12 cells.
MacKillop, EA; Ryde, IT; Seidler, FJ; Slotkin, TA, 2007
)
0.34
" Safety and tolerability were assessed by monitoring adverse events, vital signs, and physical and laboratory parameters."( Safety and tolerability of dexmecamylamine (TC-5214) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to antidepressant therapy: results of a long-term study.
Desai, D; Dunbar, G; Eriksson, H; Hosford, D; Szamosi, J; Tummala, R; Wilson, E, 2015
)
0.71

Pharmacokinetics

Mecamylamine seems to modify both the pharmacokinetic profile of alcohol and the rewarding effects of alcohol in healthy volunteers.

ExcerptReferenceRelevance
" Breath alcohol level (BAL) was examined to identify the ascending and descending limbs of the blood alcohol curve and to assess pharmacokinetic interactions between alcohol and mecamylamine."( Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol.
Blomqvist, O; Hernandez-Avila, CA; Kranzler, HR; Rose, JE; Van Kirk, J, 2002
)
1.95
"Mecamylamine seems to modify both the pharmacokinetic profile of alcohol and the rewarding effects of alcohol in healthy volunteers."( Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol.
Blomqvist, O; Hernandez-Avila, CA; Kranzler, HR; Rose, JE; Van Kirk, J, 2002
)
3.2
"As a preliminary to development and evaluation of labeled mecamylamine as a potential in vivo imaging ligand for human central nicotinic receptors (nAchRs), this work was intended to determine whether the pharmacokinetic properties of mecamylamine are suitable for experimental studies using (11)C-radiolabeled mecamylamine preliminary to positron emission tomography (PET) in humans."( Short-term pharmacokinetics and brain distribution of mecamylamine as a preliminary to carbon-11 labeling for nicotinic receptor investigation.
Barré, L; Camsonne, R; Coquerel, A; Debruyne, D; Hinschberger, A; Sobrio, F, 2003
)
0.81
" A comprehensive population pharmacokinetic (POP PK) model of TC-5214 was developed using nonlinear mixed-effects modeling of pooled plasma concentration data from 6 early phase I studies in 179 healthy participants or patients with non-MDD and 1 phase II study in 68 MDD patients."( Population pharmacokinetics of TC-5214, a nicotinic channel modulator, in phase I and II clinical studies.
Al-Huniti, N; Alverlind, S; Beaver, JS; Henningsson, A; Toler, S; Tummala, R; Xu, H, 2014
)
0.4
" The objective was to develop a pharmacokinetic-pharmacodynamic (PKPD) model using nonlinear mixed effects (NLME) methods to quantitate the pharmacokinetics of three oral mecamylamine doses (10, 20 and 30 mg) and correlate the plasma concentrations to the pharmacodynamic effects on a cognitive and neurophysiologic battery of tests in healthy subjects."( Pharmacokinetics and pharmacodynamics of oral mecamylamine - development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation.
Alvarez-Jimenez, R; Baakman, AC; Goulooze, SC; Groeneveld, GJ; Hart, EP; Rissmann, R; Stevens, J; van Gerven, JM, 2017
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
"Atropine, in combination with 1 of 6 other drugs, was tested in mice for the ability to prevent death by an otherwise lethal dose of the cholinesterase inhibitor, physostigmine."( Efficacy and toxicity of drug combinations in treatment of physostigmine toxicosis.
Klemm, WR, 1983
)
0.27
" By contrast, the same drug combination treatment did not reduce the somatic signs of nicotine withdrawal indicating symptom-specific neurobiological abnormalities."( Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats.
Harrison, AA; Liem, YT; Markou, A, 2001
)
0.31
") treated chronically (14 days) alone and in a combination with low dose of 17beta-estradiol (0."( [Chronic administration of RJR-2403 in combination with low-dose of 17beta-estradiol corrects passive avoidance learning in ovariectomized rats].
Fedotova, IuO; Sapronov, NS, 2013
)
0.39
" Our results suggest that mecamylamine produces a better antidepressant efficacy in combination with l-NAME than with l-arginine."( Better antidepressant efficacy of mecamylamine in combination with L-NAME than with L-arginine.
Ebrahimi-Ghiri, M; Mohammadi-Mahdiabadi-Hasani, MH; Nasehi, M; Zarrindast, MR, 2020
)
1.14

Bioavailability

ExcerptReferenceRelevance
" All were well absorbed when administered orally."( The pharmacological actions of pempidine and its ethyl homologue.
DUNLOP, D; FARRINGTON, JA; SPINKS, A; YOUNG, EH, 1958
)
0.24
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

A dose-response study showed that mecamylamine significantly decreased immobility time in the TST at the 1mg/kg level. A series of studies was designed to assess the effect of nicotine on REM sleep measured during the first 4 h after injection.

ExcerptRelevanceReference
" Mecamylamine shifted the dose-response curves for nicotine to the right with a gradual depression."( Comparative studies on anti-nicotinic action of hexamethonium, mecamylamine and adenosine in the guinea pig isolated ileum.
Hayashi, E; Mori, M; Yamada, S, 1977
)
1.41
" Within regions intermediate between the dorsal posterior, mesencephalic tegmentum and posterior medulla, (-)-nicotine produced biphasic dose-response and time action curves."( Opioid and nicotinic analgesic and hyperalgesic loci in the rat brain stem.
Hamann, SR; Martin, WR, 1992
)
0.28
" isoproterenol tachycardia dose-response curves by dose ratios of 5, 18, and 90 in sham rabbits, respectively, and 5, 11, and 23 in wrap rabbits, respectively, indicating significant cardiac beta 1-adrenoceptor antagonism."( Relationship between the sympatholytic action of nebivolol and hypotension.
Angus, JA; Coles, P; Cox, H; Eisenhofer, G; Ward, JE, 1992
)
0.28
" The alteration of nicotine's dose-response curves for depression of spontaneous activity and antinociception was determined in the presence of increasing concentrations of pempidine."( Pharmacological evaluation of the antagonism of nicotine's central effects by mecamylamine and pempidine.
Martin, BR; Martin, TJ; May, EL; Suchocki, J, 1990
)
0.51
" The shifts caused by atropine and pirenzepine in the dose-response curves for ACh were not parallel after in vitro treatment of the muscle with DFP."( Contractile responses of tracheal smooth muscle in organophosphate-treated swine: 2. Effects of antagonists.
Dwyer, TM; Farley, JM; Murali Mohan, P; Yang, CM, 1988
)
0.27
" After drug combinations had been tested, the nicotine dose-response curve was unchanged from its previous values, and naltrexone alone produced no tendency to decrease response rate."( Evidence for opioid mechanisms in the behavioral effects of nicotine.
Coen, KM; Corrigall, WA; Herling, S, 1988
)
0.27
" Using a statistical method developed for the CPP paradigm, dose-response curves were obtained for the rewarding and aversive effects of nicotine as measured by its ability to alter previously determined baseline preferences obtained from the control animals."( Pharmacologic characterization of nicotine-induced conditioned place preference.
Fudala, PJ; Iwamoto, ET; Teoh, KW, 1985
)
0.27
" To determine the time after administration of nicotine and dosage for neurochemical studies, locomotor activity of CD-1 mice was determined at 5 min intervals between 0-60 min."( Locomotor activity as a predictor of times and dosages for studies of nicotine's neurochemical actions.
Freeman, GB; Gibson, GE; Sherman, KA, 1987
)
0.27
" In different groups of rats trained to discriminate nicotine or midazolam separately from saline, neither drug appreciably altered the dose-response curve for the other, suggesting a minimal role for pharmacological interactions when effects of mixtures were assessed."( Discriminative stimulus effects of a nicotine-midazolam mixture in rats.
Norris, EA; Rauch, RJ; Stolerman, IP, 1987
)
0.27
" Relative potencies of the drugs were determined from dose-response relationships and the rank order of effectiveness was as follows: carbachol much greater than levamisole greater than pyrantel greater than morantel."( Actions of potent cholinergic anthelmintics (morantel, pyrantel and levamisole) on an identified insect neurone reveal pharmacological differences between nematode and insect acetylcholine receptors.
Gration, KA; Harrow, ID; Pinnock, RD; Sattelle, DB, 1988
)
0.27
" After bleeding so that arterial pressure fell to 40 mmHg, the dose-response relationship for naloxone had two components."( Factors influencing the effects of intravenous naloxone on arterial pressure and heart rate after haemorrhage in conscious rabbits.
Ludbrook, J; Potocnik, SJ; Rutter, PC, 1986
)
0.27
" The final experiment found that repeated dosing with one 2 mg NNS on an hourly schedule for six hours produced a reliable increase in tapping speed after each dose with no evidence of acute tolerance."( Effects of nicotine on finger tapping rate in non-smokers.
Jarvis, MJ; West, RJ, 1986
)
0.27
" Neither (+)- nor (-)-BN altered blood pressure and heart rate in rats in this dosage range."( Pharmacological effects of 1,2,3,5,6,10b-hexahydropyrido[2,3g]indolizine, a bridged-nicotine analog.
Aceto, MD; Awaya, H; Egle, JL; Kachur, JF; Martin, BR; May, EL, 1986
)
0.27
" In both species at 30 min after im injection of Py and Ph, a linear relationship was found between percentage of whole blood AChE inhibition and ln dosage of carbamate."( Relationship between reversible acetylcholinesterase inhibition and efficacy against soman lethality.
Anderson, DR; Harris, LW; Lennox, WJ; Talbot, BG, 1985
)
0.27
"), a nicotinic antagonist with both central and peripheral effects, shifted the nicotine dose-response curve to the right by about 1 log unit and blocked nicotine-induced emesis."( Maintenance of behavior by postponement of scheduled injections of nicotine in squirrel monkeys.
Spealman, RD, 1983
)
0.27
" Dose-response relationships for optically pure (-)- and (+)nicotine as well as antagonistic effects were examined in both groups of rats."( Discriminative stimulus properties of the optical isomers of nicotine.
Aceto, MD; Harris, LS; Meltzer, LT; Rosecrans, JA, 1980
)
0.26
" The whole-cell dose-response curve suggests that activation of current by ACh increases up to at least 100 microM and that multiple ligand binding steps are involved."( Activation of nicotinic acetylcholine receptors on cultured Drosophila and other insect neurones.
Albert, JL; Lingle, CJ, 1993
)
0.29
") were found to enhance nicotine-induced antinociception by shifting its dose-response curve to the left."( Involvement of calcium and L-type channels in nicotine-induced antinociception.
Damaj, MI; Martin, BR; Welch, SP, 1993
)
0.29
" Recently we found that spinal intrathecal administration of nicotine dose-dependently inhibits bradykinin-induced plasma extravasation (BK-induced PE) in the knee joint of the rat and that the dose-response curve for the inhibition of BK-induced PE by intrathecal nicotine is shifted to the left, by six orders of magnitude, after surgical interventions in the abdominal cavity, which might have interrupted visceral afferents to the neuraxis."( Role of vagal afferents and spinal pathways modulating inhibition of bradykinin-induced plasma extravasation by intrathecal nicotine.
Basbaum, AI; Benowitz, NL; Dallman, MF; Heller, PH; Jänig, W; Levine, JD; Miao, FJ, 1994
)
0.29
" The cholinergic antagonists exerted complex changes in the ONR-ON component depending on dosage and adaptation."( Cholinergic effects on cat retina In vitro: changes in rod- and cone-driven b-wave and optic nerve response.
Jurklies, B; Kaelin-Lang, A; Niemeyer, G, 1996
)
0.29
" When dose per infusion was varied, an inverted U-shaped dose-response curve was obtained."( Nicotine self-administration in rats: strain and nicotine pre-exposure effects on acquisition.
Goldberg, SR; Schindler, CW; Shoaib, M, 1997
)
0.3
" (-)-Nicotine exhibited a bell-shaped dose-response relationship, and showed attenuation of response at the highest dose (5."( Pharmacological characterization of nicotinic receptor-mediated acetylcholine release in rat brain--an in vivo microdialysis study.
Imoto, M; Ohno, T; Saito, K; Tani, Y, 1998
)
0.3
" The lack of a clear dose-response relationship for the agonist and the antagonist indicates that the interaction between the NAc nicotinic system and ETOH self-administration is complex."( Effects of nicotine and mecamylamine microinjections into the nucleus accumbens on ethanol and sucrose self-administration.
Chappell, AM; Nadal, R; Samson, HH, 1998
)
0.61
" The pattern of shift of the dose-response curve for nicotine-induced convulsion in mice was determined in the presence of increasing concentrations of the anticholinergic antiparkinson drugs."( Anti-nicotinic properties of anticholinergic antiparkinson drugs.
Cui, WY; Fan, QH; Gao, ZG; Li, LJ; Liu, BY; Liu, CG, 1998
)
0.3
" Results from extinction tests showed that all groups of mice yielded orderly dose-response curves for nicotine (0."( Discrimination and self-administration of nicotine by inbred strains of mice.
Elmer, GI; Goldberg, SR; Naylor, C; Stolerman, IP, 1999
)
0.3
"Male Wistar rats were prepared with a set of sleep recording electrodes and, following habituation to the test chamber, were used in one of three studies: a) a dose-response analysis of an acute dose of nicotine on REM sleep measured during the first 4 h after injection; b) a chronic treatment experiment; or c) a mecamylamine blockade experiment."( Changes in sleep after acute and repeated administration of nicotine in the rat.
Blanco-Centurion, C; Gonzalez-Sanchez, H; Moro-Lopez, ML; Salin-Pascual, RJ, 1999
)
0.48
"6 mg/kg) was dose-related, but the dose-response relationship was not dependent upon the presence of midazolam."( Nicotine trace discrimination in rats with midazolam as a mediating stimulus.
Mariathasan, EA; Stolerman, IP, 2003
)
0.32
" Both markers co-varied with a similar dose-response and time course after the nicotine-treatment."( Nicotine-induced inflammatory decreasing effect on passive skin arthus reaction in paraventricular nucleus-lesioned wistar rats.
Kita, T; Kubo, K; Nakashima, T; Nakatani, T; Narushima, I; Tanaka, T, 2003
)
0.32
" The present study determined the dose-response for nicotine (0."( Nicotinic receptor modulation of dopamine transporter function in rat striatum and medial prefrontal cortex.
Cass, WA; Dwoskin, LP; Middleton, LS, 2004
)
0.32
" Nefiracetam potentiated alpha4beta2-like ACh- and NMDA-induced currents at nanomolar concentrations forming bell-shaped dose-response curves with the maximum potentiation occurring at 1 and 10 nM, respectively."( Unique mechanism of action of Alzheimer's drugs on brain nicotinic acetylcholine receptors and NMDA receptors.
Marszalec, W; Moriguchi, S; Narahashi, T; Yeh, JZ; Zhao, X, 2003
)
0.32
" We have performed a dose-response study for intrahippocampal nicotine (CA1) on acquisition and extinction of the lever-press response and antagonization test by co-administration of mecamylamine."( Intrahippocampal nicotine in alcohol drinking rats--effects on lever-press response.
Darbra, S; Ferré, N; García-Rebollo, Y, 2005
)
0.52
" Both agents produced a marked downward shift in the nicotine dose-response curve."( Drug discrimination analysis of NMDA receptor channel blockers as nicotinic receptor antagonists in rats.
Bespalov, AY; Danysz, W; Zakharova, ES, 2005
)
0.33
" via osmotic minipumps that delivered various nicotine dosage regimens, some including 24-h nicotine-free periods, to manipulate pattern of exposure."( Dose, duration, and pattern of nicotine administration as determinants of behavioral dependence in rats.
Balster, RL; Beardsley, PM; Vann, RE, 2006
)
0.33
"Adolescents did not display the decreases in brain reward function observed in adults experiencing withdrawal, and displayed fewer somatic signs of nicotine withdrawal relative to adults regardless of the dosing procedure used."( Diminished nicotine withdrawal in adolescent rats: implications for vulnerability to addiction.
Bruijnzeel, AW; Goldberger, BA; Koob, GF; Markou, A; Merves, ML; O'Dell, LE; Parsons, LH; Richardson, HN; Smith, RT, 2006
)
0.33
" Both nicotine and the nicotinic alpha-7 selective agonist AR-17779 significantly increased cell proliferation albeit with bell-shaped dose-response kinetics."( Nicotine regulates SH-SY5Y neuroblastoma cell proliferation through the release of brain-derived neurotrophic factor.
Carney, SL; Serres, F, 2006
)
0.33
" Dose-response curves for fchi increases evoked by intra-stream boluses of acetylcholine, nicotine and ATP were studied."( Effects of combined cholinergic-purinergic block upon cat carotid body chemoreceptors in vitro.
Fernández, R; Larraín, C; Reyes, EP; Zapata, P, 2007
)
0.34
" For rats with access to VS (VS-Only), nicotine (NIC-Only), both reinforcers contingent upon one response (NIC+VS) or both reinforcers contingent upon separate responses (2-Lever), unit dose-response relationships (0, 30, 60, or 90 microg/kg/infusion, free base) were determined over a 22-day acquisition period."( The role of nicotinic acetylcholine receptors in the primary reinforcing and reinforcement-enhancing effects of nicotine.
Caggiula, AR; Donny, EC; Liu, X; Palmatier, MI; Sved, AF, 2007
)
0.34
" In the abdominal constriction test, LXM-10 had a significant dose-response effect, and the maximal inhibition ratio was 79."( Antinociceptive effects of the novel spirocyclopiperazinium salt compound LXM-10 in mice.
Li, CL; Li, RT; Sun, Q; Ye, J; Yue, CQ, 2007
)
0.34
" This hypothesis was further established with methyllycaconitine completely inhibited the agonist effect when dosed intrathecally (1% +/- 7%)."( Activation of the alpha7-nicotinic acetylcholine receptor reverses complete freund adjuvant-induced mechanical hyperalgesia in the rat via a central site of action.
Billinton, A; Bingham, S; Chessell, IP; Clayton, NM; Hatcher, JP; Hille, CJ; Medhurst, SJ, 2008
)
0.35
" At higher dosage (500 microM) AP height was reduced, conduction velocity slowed, and conduction failure occurred, especially during hypoxia, producing the appearance of a decreased response to hypoxia."( Nicotinic acetylcholine receptors do not mediate excitatory transmission in young rat carotid body.
Donnelly, DF, 2009
)
0.35
" Mecamylamine (1mg/kg) produced parallel rightward shifts in the dose-response curves for nicotine (3."( The effects of nicotine, varenicline, and cytisine on schedule-controlled responding in mice: differences in α4β2 nicotinic receptor activation.
Cunningham, CS; McMahon, LR, 2011
)
1.28
"A series of studies was designed to assess the acute dose-response effects of nicotine and the nicotinic receptor antagonist mecamylamine alone, and in combination with nicotine, on impulsive choice and behavioural disinhibition in rats."( Acute nicotine increases both impulsive choice and behavioural disinhibition in rats.
Harrison, AA; Kolokotroni, KZ; Rodgers, RJ, 2011
)
0.58
"The study had evaluated the dose-response curves for nicotine and KA and for KA in nicotine-pretreated mice and for topiramate against KA-induced seizures."( Nicotine reversal of anticonvulsant action of topiramate in kainic acid-induced seizure model in mice.
Chakrabarti, A; Hota, D; Sahai, AK; Sood, N, 2011
)
0.37
" We found that despite the differences in methodological approaches between these technologies, the EC(50) values from the ACh dose-response curves were consistent between all three platforms."( Validation of a high-throughput, automated electrophysiology platform for the screening of nicotinic agonists and antagonists.
Bencherif, M; Benson, LC; Fedorov, NB; Graef, JD; Lippiello, PM; Sidach, SS; Wei, H, 2013
)
0.39
"Low and high doses of NIC, cytisine (CYT), CC4 and CC26 respectively improved and worsened the mean running time, showing an inverted U dose-response function."( Role of neuronal nicotinic acetylcholine receptors (nAChRs) on learning and memory in zebrafish.
Braida, D; Gotti, C; Martucci, R; Ponzoni, L; Sala, M; Sparatore, F, 2014
)
0.4
" The proposed final POP PK model could be employed in defining a TC-5214 dosage regimen in patients with impaired renal function."( Population pharmacokinetics of TC-5214, a nicotinic channel modulator, in phase I and II clinical studies.
Al-Huniti, N; Alverlind, S; Beaver, JS; Henningsson, A; Toler, S; Tummala, R; Xu, H, 2014
)
0.4
" Coexpression of α6β4 nAChRs with P2X3 receptors shifts the ATP dose-response relation to the right, even in the absence of acetylcholine (ACh)."( Subtype-specific mechanisms for functional interaction between α6β4* nicotinic acetylcholine receptors and P2X receptors.
Dougherty, DA; Lester, HA; Limapichat, W, 2014
)
0.4
" Patients were randomized 3:1 to receive flexibly dosed dexmecamylamine 1 to 4 mg adjunct to SSRI/SNRI or placebo plus SSRI/SNRI."( Safety and tolerability of dexmecamylamine (TC-5214) adjunct to ongoing antidepressant therapy in patients with major depressive disorder and an inadequate response to antidepressant therapy: results of a long-term study.
Desai, D; Dunbar, G; Eriksson, H; Hosford, D; Szamosi, J; Tummala, R; Wilson, E, 2015
)
0.95
" Further development of these models, including evaluation of more clinically relevant nicotine dosing regimens and other measures of nicotine withdrawal (e."( A Two-Day Continuous Nicotine Infusion Is Sufficient to Demonstrate Nicotine Withdrawal in Rats as Measured Using Intracranial Self-Stimulation.
Harris, AC; Muelken, P; Schmidt, CE; Shelley, D; Tally, L, 2015
)
0.42
", by reaching the high end of a nicotinic receptor activation inverted-U dose-response function."( Attenuation in rats of impairments of memory by scopolamine, a muscarinic receptor antagonist, by mecamylamine, a nicotinic receptor antagonist.
Gold, PE; Newman, LA, 2016
)
0.65
" Preclinical research is imperative for understanding the addictive properties and health-risks associated with ECIG use; however, there is not a standard dosing regimen used across research laboratories."( Nicotine-free vapor inhalation produces behavioral disruptions and anxiety-like behaviors in mice: Effects of puff duration, session length, sex, and flavor.
Allen, N; Barraza, AG; Dewey, M; Garrett, PI; Hillhouse, TM; Honeycutt, SC; Marston, C; Peterson, AM; Turner, B, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
primary aliphatic amine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (30)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATAD5 protein, partialHomo sapiens (human)Potency16.35350.004110.890331.5287AID493107
GLS proteinHomo sapiens (human)Potency19.95260.35487.935539.8107AID624146
regulator of G-protein signaling 4Homo sapiens (human)Potency1.33710.531815.435837.6858AID504845
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency2.13140.000214.376460.0339AID720691
arylsulfatase AHomo sapiens (human)Potency8.49211.069113.955137.9330AID720538
thyroid stimulating hormone receptorHomo sapiens (human)Potency0.08410.001628.015177.1139AID1259385
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency35.48130.01789.637444.6684AID588834
lamin isoform A-delta10Homo sapiens (human)Potency11.22020.891312.067628.1838AID1487
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Neuronal acetylcholine receptor subunit beta-2Homo sapiens (human)IC50 (µMol)0.44000.00110.539010.0000AID241632; AID761289
Neuronal acetylcholine receptor subunit beta-4Homo sapiens (human)IC50 (µMol)4.07140.00181.67796.5000AID146166; AID241631; AID241633; AID761288
Neuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)IC50 (µMol)1.61330.00181.31326.5000AID146166; AID241632; AID241633; AID761288
Neuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)IC50 (µMol)7.05000.00204.15279.9000AID225715; AID241410
Neuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)IC50 (µMol)0.60000.00110.491110.0000AID761289
Neuronal acetylcholine receptor subunit alpha-2Homo sapiens (human)IC50 (µMol)9.55003.10003.10003.1000AID241631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Acetylcholine receptor subunit alphaHomo sapiens (human)EC50 (µMol)30.00000.00013.337010.0000AID145358
Neuronal acetylcholine receptor subunit alpha-3Rattus norvegicus (Norway rat)EC50 (µMol)0.20000.00001.011610.0000AID145658
Acetylcholine receptor subunit gammaHomo sapiens (human)EC50 (µMol)30.00000.00010.00550.0110AID145358
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)EC50 (µMol)0.20000.01402.272410.0000AID145658
Acetylcholine receptor subunit betaHomo sapiens (human)EC50 (µMol)30.00000.00010.00550.0110AID145358
Neuronal acetylcholine receptor subunit alpha-2Rattus norvegicus (Norway rat)EC50 (µMol)0.20000.10002.104010.0000AID145658
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)EC50 (µMol)0.20000.01402.310410.0000AID145658
Neuronal acetylcholine receptor subunit beta-3Rattus norvegicus (Norway rat)EC50 (µMol)0.20000.04601.761010.0000AID145658
Neuronal acetylcholine receptor subunit beta-4Rattus norvegicus (Norway rat)EC50 (µMol)0.20000.00001.010110.0000AID145658
Neuronal acetylcholine receptor subunit alpha-5Rattus norvegicus (Norway rat)EC50 (µMol)0.20000.10002.104010.0000AID145658
Neuronal acetylcholine receptor subunit alpha-6Rattus norvegicus (Norway rat)EC50 (µMol)0.20000.04601.761010.0000AID145658
Neuronal acetylcholine receptor subunit alpha-9Rattus norvegicus (Norway rat)EC50 (µMol)0.20000.10002.104010.0000AID145658
Neuronal acetylcholine receptor subunit alpha-7Rattus norvegicus (Norway rat)EC50 (µMol)0.20000.00021.848110.0000AID145658
Acetylcholine receptor subunit deltaHomo sapiens (human)EC50 (µMol)30.00000.00010.00550.0110AID145358
Neuronal acetylcholine receptor subunit alpha-10Rattus norvegicus (Norway rat)EC50 (µMol)0.20000.10002.104010.0000AID145658
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Neuronal acetylcholine receptor subunit beta-2Homo sapiens (human)Concentration0.78000.78005.390010.0000AID244295
Neuronal acetylcholine receptor subunit beta-4Homo sapiens (human)Concentration1.62000.56001.62003.1000AID244297
Neuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)Concentration1.41000.56003.128010.0000AID244295; AID244297
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (93)

Processvia Protein(s)Taxonomy
neuromuscular synaptic transmissionAcetylcholine receptor subunit alphaHomo sapiens (human)
neuromuscular junction developmentAcetylcholine receptor subunit alphaHomo sapiens (human)
regulation of membrane potentialAcetylcholine receptor subunit alphaHomo sapiens (human)
skeletal muscle contractionAcetylcholine receptor subunit alphaHomo sapiens (human)
monoatomic cation transportAcetylcholine receptor subunit alphaHomo sapiens (human)
neuronal action potentialAcetylcholine receptor subunit alphaHomo sapiens (human)
monoatomic ion transmembrane transportAcetylcholine receptor subunit alphaHomo sapiens (human)
regulation of membrane potentialAcetylcholine receptor subunit alphaHomo sapiens (human)
muscle cell cellular homeostasisAcetylcholine receptor subunit alphaHomo sapiens (human)
skeletal muscle tissue growthAcetylcholine receptor subunit alphaHomo sapiens (human)
musculoskeletal movementAcetylcholine receptor subunit alphaHomo sapiens (human)
neuromuscular processAcetylcholine receptor subunit alphaHomo sapiens (human)
excitatory postsynaptic potentialAcetylcholine receptor subunit alphaHomo sapiens (human)
neuron cellular homeostasisAcetylcholine receptor subunit alphaHomo sapiens (human)
membrane depolarizationAcetylcholine receptor subunit alphaHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholine receptor subunit alphaHomo sapiens (human)
response to nicotineAcetylcholine receptor subunit alphaHomo sapiens (human)
synaptic transmission, cholinergicAcetylcholine receptor subunit alphaHomo sapiens (human)
muscle contractionAcetylcholine receptor subunit gammaHomo sapiens (human)
signal transductionAcetylcholine receptor subunit gammaHomo sapiens (human)
synaptic transmission, cholinergicAcetylcholine receptor subunit gammaHomo sapiens (human)
monoatomic ion transmembrane transportAcetylcholine receptor subunit gammaHomo sapiens (human)
excitatory postsynaptic potentialAcetylcholine receptor subunit gammaHomo sapiens (human)
membrane depolarizationAcetylcholine receptor subunit gammaHomo sapiens (human)
chemical synaptic transmissionAcetylcholine receptor subunit gammaHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholine receptor subunit gammaHomo sapiens (human)
postsynaptic membrane organizationAcetylcholine receptor subunit betaHomo sapiens (human)
monoatomic cation transportAcetylcholine receptor subunit betaHomo sapiens (human)
muscle contractionAcetylcholine receptor subunit betaHomo sapiens (human)
signal transductionAcetylcholine receptor subunit betaHomo sapiens (human)
synaptic transmission, cholinergicAcetylcholine receptor subunit betaHomo sapiens (human)
neuromuscular synaptic transmissionAcetylcholine receptor subunit betaHomo sapiens (human)
monoatomic ion transmembrane transportAcetylcholine receptor subunit betaHomo sapiens (human)
behavioral response to nicotineAcetylcholine receptor subunit betaHomo sapiens (human)
regulation of membrane potentialAcetylcholine receptor subunit betaHomo sapiens (human)
nervous system processAcetylcholine receptor subunit betaHomo sapiens (human)
muscle cell developmentAcetylcholine receptor subunit betaHomo sapiens (human)
excitatory postsynaptic potentialAcetylcholine receptor subunit betaHomo sapiens (human)
membrane depolarizationAcetylcholine receptor subunit betaHomo sapiens (human)
chemical synaptic transmissionAcetylcholine receptor subunit betaHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholine receptor subunit betaHomo sapiens (human)
response to hypoxiaNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
monoatomic ion transportNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
calcium ion transportNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
smooth muscle contractionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
signal transductionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
synaptic transmission, cholinergicNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
visual perceptionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
sensory perception of soundNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
learningNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
memoryNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
locomotory behaviorNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
associative learningNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
visual learningNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of dopamine secretionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
sensory perception of painNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
vestibulocochlear nerve developmentNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
optic nerve morphogenesisNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
lateral geniculate nucleus developmentNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
central nervous system projection neuron axonogenesisNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
positive regulation of B cell proliferationNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of synaptic transmission, dopaminergicNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
positive regulation of dopamine secretionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
monoatomic ion transmembrane transportNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
response to nicotineNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
behavioral response to nicotineNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
social behaviorNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of dopamine metabolic processNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
B cell activationNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
response to cocaineNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of circadian sleep/wake cycle, REM sleepNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
response to ethanolNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
negative regulation of action potentialNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of dendrite morphogenesisNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
nervous system processNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
cognitionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
membrane depolarizationNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
regulation of synapse assemblyNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
synaptic transmission involved in micturitionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
acetylcholine receptor signaling pathwayNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
response to acetylcholineNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
chemical synaptic transmissionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
monoatomic ion transportNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
smooth muscle contractionNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
regulation of smooth muscle contractionNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
signal transductionNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
synaptic transmission, cholinergicNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
locomotory behaviorNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
neuronal action potentialNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
monoatomic ion transmembrane transportNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
behavioral response to nicotineNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
regulation of neurotransmitter secretionNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
positive regulation of transmission of nerve impulseNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
synaptic transmission involved in micturitionNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
chemical synaptic transmissionNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
acetylcholine receptor signaling pathwayNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
membrane depolarizationNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
monoatomic ion transportNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
regulation of smooth muscle contractionNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
signal transductionNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
activation of transmembrane receptor protein tyrosine kinase activityNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
synaptic transmission, cholinergicNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
nervous system developmentNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
locomotory behaviorNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
regulation of acetylcholine secretion, neurotransmissionNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
monoatomic ion transmembrane transportNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
behavioral response to nicotineNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
regulation of membrane potentialNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
regulation of dendrite morphogenesisNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
synaptic transmission involved in micturitionNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
acetylcholine receptor signaling pathwayNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
response to acetylcholineNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
response to nicotineNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
membrane depolarizationNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
negative regulation of tumor necrosis factor productionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
response to hypoxiaNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of protein phosphorylationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
monoatomic ion transportNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
calcium ion transportNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
intracellular calcium ion homeostasisNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
signal transductionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
synaptic transmission, cholinergicNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
learning or memoryNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
memoryNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
short-term memoryNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of cell population proliferationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
negative regulation of tumor necrosis factor productionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
monoatomic ion transmembrane transportNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
response to nicotineNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of MAPK cascadeNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of angiogenesisNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
synapse organizationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
cognitionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
sensory processingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of protein metabolic processNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
calcium ion transmembrane transportNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine receptor signaling pathwayNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
dendritic spine organizationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
modulation of excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
dendrite arborizationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of long-term synaptic potentiationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of amyloid-beta formationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
negative regulation of amyloid-beta formationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
regulation of amyloid precursor protein catabolic processNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
response to amyloid-betaNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
response to acetylcholineNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
regulation of amyloid fibril formationNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of CoA-transferase activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
positive regulation of excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
regulation of membrane potentialNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
chemical synaptic transmissionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
action potentialNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
response to hypoxiaNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
DNA repairNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
monoatomic ion transportNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
calcium ion transportNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
response to oxidative stressNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
signal transductionNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
chemical synaptic transmissionNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
synaptic transmission, cholinergicNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
regulation of dopamine secretionNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
sensory perception of painNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
monoatomic ion transmembrane transportNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
response to nicotineNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
behavioral response to nicotineNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
B cell activationNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
regulation of membrane potentialNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
nervous system processNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
cognitionNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
membrane depolarizationNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
inhibitory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine receptor signaling pathwayNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
muscle contractionAcetylcholine receptor subunit epsilonHomo sapiens (human)
signal transductionAcetylcholine receptor subunit epsilonHomo sapiens (human)
synaptic transmission, cholinergicAcetylcholine receptor subunit epsilonHomo sapiens (human)
excitatory postsynaptic potentialAcetylcholine receptor subunit epsilonHomo sapiens (human)
monoatomic cation transmembrane transportAcetylcholine receptor subunit epsilonHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholine receptor subunit epsilonHomo sapiens (human)
membrane depolarizationAcetylcholine receptor subunit epsilonHomo sapiens (human)
monoatomic ion transmembrane transportAcetylcholine receptor subunit epsilonHomo sapiens (human)
chemical synaptic transmissionAcetylcholine receptor subunit epsilonHomo sapiens (human)
skeletal muscle contractionAcetylcholine receptor subunit deltaHomo sapiens (human)
monoatomic cation transportAcetylcholine receptor subunit deltaHomo sapiens (human)
muscle contractionAcetylcholine receptor subunit deltaHomo sapiens (human)
signal transductionAcetylcholine receptor subunit deltaHomo sapiens (human)
synaptic transmission, cholinergicAcetylcholine receptor subunit deltaHomo sapiens (human)
monoatomic ion transmembrane transportAcetylcholine receptor subunit deltaHomo sapiens (human)
skeletal muscle tissue growthAcetylcholine receptor subunit deltaHomo sapiens (human)
musculoskeletal movementAcetylcholine receptor subunit deltaHomo sapiens (human)
neuromuscular processAcetylcholine receptor subunit deltaHomo sapiens (human)
excitatory postsynaptic potentialAcetylcholine receptor subunit deltaHomo sapiens (human)
acetylcholine receptor signaling pathwayAcetylcholine receptor subunit deltaHomo sapiens (human)
chemical synaptic transmissionAcetylcholine receptor subunit deltaHomo sapiens (human)
membrane depolarizationAcetylcholine receptor subunit deltaHomo sapiens (human)
monoatomic ion transportNeuronal acetylcholine receptor subunit alpha-2Homo sapiens (human)
signal transductionNeuronal acetylcholine receptor subunit alpha-2Homo sapiens (human)
monoatomic ion transmembrane transportNeuronal acetylcholine receptor subunit alpha-2Homo sapiens (human)
excitatory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-2Homo sapiens (human)
cellular response to nicotineNeuronal acetylcholine receptor subunit alpha-2Homo sapiens (human)
modulation of inhibitory postsynaptic potentialNeuronal acetylcholine receptor subunit alpha-2Homo sapiens (human)
membrane depolarizationNeuronal acetylcholine receptor subunit alpha-2Homo sapiens (human)
acetylcholine receptor signaling pathwayNeuronal acetylcholine receptor subunit alpha-2Homo sapiens (human)
response to nicotineNeuronal acetylcholine receptor subunit alpha-2Homo sapiens (human)
synaptic transmission, cholinergicNeuronal acetylcholine receptor subunit alpha-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
acetylcholine receptor activityAcetylcholine receptor subunit alphaHomo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityAcetylcholine receptor subunit alphaHomo sapiens (human)
acetylcholine bindingAcetylcholine receptor subunit alphaHomo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityAcetylcholine receptor subunit alphaHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialAcetylcholine receptor subunit alphaHomo sapiens (human)
protein bindingAcetylcholine receptor subunit gammaHomo sapiens (human)
channel activityAcetylcholine receptor subunit gammaHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialAcetylcholine receptor subunit gammaHomo sapiens (human)
acetylcholine receptor activityAcetylcholine receptor subunit gammaHomo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityAcetylcholine receptor subunit gammaHomo sapiens (human)
acetylcholine receptor activityAcetylcholine receptor subunit betaHomo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityAcetylcholine receptor subunit betaHomo sapiens (human)
protein bindingAcetylcholine receptor subunit betaHomo sapiens (human)
channel activityAcetylcholine receptor subunit betaHomo sapiens (human)
ligand-gated monoatomic ion channel activityAcetylcholine receptor subunit betaHomo sapiens (human)
acetylcholine bindingAcetylcholine receptor subunit betaHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialAcetylcholine receptor subunit betaHomo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityAcetylcholine receptor subunit betaHomo sapiens (human)
protein bindingNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
ligand-gated monoatomic ion channel activityNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
acetylcholine receptor activityNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
acetylcholine bindingNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
protein-containing complex bindingNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
quaternary ammonium group bindingNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
heterocyclic compound bindingNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
protein bindingNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
ligand-gated monoatomic ion channel activityNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
acetylcholine receptor activityNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
protein bindingNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
ligand-gated monoatomic ion channel activityNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
acetylcholine receptor activityNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
acetylcholine bindingNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
amyloid-beta bindingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
monoatomic ion channel activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
calcium channel activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
protein bindingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine receptor activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
toxic substance bindingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
chloride channel regulator activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine bindingNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
protein homodimerization activityNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
protein bindingNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
ligand-gated monoatomic ion channel activityNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine receptor activityNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine bindingNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
monoatomic cation transmembrane transporter activityAcetylcholine receptor subunit epsilonHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialAcetylcholine receptor subunit epsilonHomo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityAcetylcholine receptor subunit epsilonHomo sapiens (human)
acetylcholine receptor activityAcetylcholine receptor subunit epsilonHomo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityAcetylcholine receptor subunit deltaHomo sapiens (human)
acetylcholine bindingAcetylcholine receptor subunit deltaHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potentialAcetylcholine receptor subunit deltaHomo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityAcetylcholine receptor subunit deltaHomo sapiens (human)
acetylcholine receptor activityAcetylcholine receptor subunit deltaHomo sapiens (human)
acetylcholine receptor activityNeuronal acetylcholine receptor subunit alpha-2Homo sapiens (human)
acetylcholine-gated monoatomic cation-selective channel activityNeuronal acetylcholine receptor subunit alpha-2Homo sapiens (human)
quaternary ammonium group bindingNeuronal acetylcholine receptor subunit alpha-2Homo sapiens (human)
heterocyclic compound bindingNeuronal acetylcholine receptor subunit alpha-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
neuromuscular junctionAcetylcholine receptor subunit alphaHomo sapiens (human)
plasma membraneAcetylcholine receptor subunit alphaHomo sapiens (human)
cell surfaceAcetylcholine receptor subunit alphaHomo sapiens (human)
neuromuscular junctionAcetylcholine receptor subunit alphaHomo sapiens (human)
postsynaptic membraneAcetylcholine receptor subunit alphaHomo sapiens (human)
postsynaptic specialization membraneAcetylcholine receptor subunit alphaHomo sapiens (human)
acetylcholine-gated channel complexAcetylcholine receptor subunit alphaHomo sapiens (human)
synapseAcetylcholine receptor subunit alphaHomo sapiens (human)
plasma membraneAcetylcholine receptor subunit alphaHomo sapiens (human)
neuron projectionAcetylcholine receptor subunit alphaHomo sapiens (human)
plasma membraneAcetylcholine receptor subunit gammaHomo sapiens (human)
postsynaptic membraneAcetylcholine receptor subunit gammaHomo sapiens (human)
acetylcholine-gated channel complexAcetylcholine receptor subunit gammaHomo sapiens (human)
plasma membraneAcetylcholine receptor subunit gammaHomo sapiens (human)
synapseAcetylcholine receptor subunit gammaHomo sapiens (human)
neuron projectionAcetylcholine receptor subunit gammaHomo sapiens (human)
neuromuscular junctionAcetylcholine receptor subunit betaHomo sapiens (human)
plasma membraneAcetylcholine receptor subunit betaHomo sapiens (human)
synapseAcetylcholine receptor subunit betaHomo sapiens (human)
postsynaptic specialization membraneAcetylcholine receptor subunit betaHomo sapiens (human)
acetylcholine-gated channel complexAcetylcholine receptor subunit betaHomo sapiens (human)
plasma membraneAcetylcholine receptor subunit betaHomo sapiens (human)
synapseAcetylcholine receptor subunit betaHomo sapiens (human)
neuron projectionAcetylcholine receptor subunit betaHomo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
external side of plasma membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
presynaptic membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
plasma membrane raftNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
cholinergic synapseNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
postsynaptic specialization membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
acetylcholine-gated channel complexNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
neuron projectionNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
synapseNeuronal acetylcholine receptor subunit beta-2Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
membraneNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
specific granule membraneNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
postsynaptic membraneNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
tertiary granule membraneNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
cholinergic synapseNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
acetylcholine-gated channel complexNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
neuron projectionNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
synapseNeuronal acetylcholine receptor subunit beta-4Homo sapiens (human)
endoplasmic reticulumNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
Golgi apparatusNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
postsynaptic densityNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
membraneNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
nuclear speckNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
dendriteNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
neuronal cell bodyNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
plasma membrane raftNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
postsynaptic membraneNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
acetylcholine-gated channel complexNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
neuron projectionNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
synapseNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-3Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
membraneNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
plasma membrane raftNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
postsynaptic membraneNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
postsynapseNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
acetylcholine-gated channel complexNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
neuron projectionNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
synapseNeuronal acetylcholine receptor subunit alpha-7Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-9Rattus norvegicus (Norway rat)
plasma membraneNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
external side of plasma membraneNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
membraneNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
dendriteNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
neuronal cell bodyNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
postsynaptic membraneNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
acetylcholine-gated channel complexNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
synapseNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
neuron projectionNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-4Homo sapiens (human)
neuromuscular junctionAcetylcholine receptor subunit epsilonHomo sapiens (human)
plasma membraneAcetylcholine receptor subunit epsilonHomo sapiens (human)
postsynaptic membraneAcetylcholine receptor subunit epsilonHomo sapiens (human)
neuron projectionAcetylcholine receptor subunit epsilonHomo sapiens (human)
acetylcholine-gated channel complexAcetylcholine receptor subunit epsilonHomo sapiens (human)
synapseAcetylcholine receptor subunit epsilonHomo sapiens (human)
plasma membraneAcetylcholine receptor subunit epsilonHomo sapiens (human)
neuromuscular junctionAcetylcholine receptor subunit deltaHomo sapiens (human)
plasma membraneAcetylcholine receptor subunit deltaHomo sapiens (human)
acetylcholine-gated channel complexAcetylcholine receptor subunit deltaHomo sapiens (human)
postsynaptic membraneAcetylcholine receptor subunit deltaHomo sapiens (human)
postsynaptic specialization membraneAcetylcholine receptor subunit deltaHomo sapiens (human)
plasma membraneAcetylcholine receptor subunit deltaHomo sapiens (human)
neuron projectionAcetylcholine receptor subunit deltaHomo sapiens (human)
synapseAcetylcholine receptor subunit deltaHomo sapiens (human)
nucleoplasmNeuronal acetylcholine receptor subunit alpha-2Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-2Homo sapiens (human)
membraneNeuronal acetylcholine receptor subunit alpha-2Homo sapiens (human)
intercellular bridgeNeuronal acetylcholine receptor subunit alpha-2Homo sapiens (human)
postsynaptic membraneNeuronal acetylcholine receptor subunit alpha-2Homo sapiens (human)
neuron projection cytoplasmNeuronal acetylcholine receptor subunit alpha-2Homo sapiens (human)
acetylcholine-gated channel complexNeuronal acetylcholine receptor subunit alpha-2Homo sapiens (human)
neuron projectionNeuronal acetylcholine receptor subunit alpha-2Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-2Homo sapiens (human)
synapseNeuronal acetylcholine receptor subunit alpha-2Homo sapiens (human)
plasma membraneNeuronal acetylcholine receptor subunit alpha-10Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (103)

Assay IDTitleYearJournalArticle
AID118198In vivo nicotinic antagonism relative to (+/-)-exo-mecamylamine measured in mice1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis of 2-exo- and 2-endo-mecamylamine analogues. Structure-activity relationships for nicotinic antagonism in the central nervous system.
AID241632Inhibitory concentration against Nicotinic acetylcholine receptor alpha3-beta22005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.
AID241631Inhibitory concentration against Nicotinic acetylcholine receptor alpha2-beta42005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.
AID244295Inhibitory concentration against Nicotinic acetylcholine receptor alpha4-beta22005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID761288Antagonist activity at human alpha3beta4 nAChR expressed in HEK-tsA201 cells assessed as inhibition of epibatidine-induced intracellular calcium level by fluorescence plate reader analysis2013Bioorganic & medicinal chemistry, Aug-01, Volume: 21, Issue:15
Discovery of benzamide analogs as negative allosteric modulators of human neuronal nicotinic receptors: pharmacophore modeling and structure-activity relationship studies.
AID23495Partition coefficient (logP)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis of 2-exo- and 2-endo-mecamylamine analogues. Structure-activity relationships for nicotinic antagonism in the central nervous system.
AID146166Inhibitory activity against nicotinic acetylcholine receptor alpha3-beta42004Bioorganic & medicinal chemistry letters, Jul-16, Volume: 14, Issue:14
Structure activity studies of ring E analogues of methyllycaconitine. Part 2: Synthesis of antagonists to the alpha3beta4* nicotinic acetylcholine receptors through modifications to the ester.
AID158040Concentration required to reduce chloroquine IC50 by 50%2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Synthesis and effects on chloroquine susceptibility in Plasmodium falciparum of a series of new dihydroanthracene derivatives.
AID30526Compounds was evaluate for their ability to enhance (+/-)-[3H]nicotine binding at a dose range 2.5*10e-9-2.5*10e-5 M was reported1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID225715Ability to block activation of acetylcholine-stimulated currents in human alpha-7 homomers expressed in oocytes1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Neuronal nicotinic acetylcholine receptors as targets for drug discovery.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID241410Inhibitory concentration against Nicotinic acetylcholine receptor alpha 72005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.
AID678721Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID736857Antagonist activity at human recombinant alpha4beta2 nAChR expressed in human HEKtsA201 cells assessed as inhibition of epibatidine-stimulated calcium accumulation at 10 uM pretreated and cotreated with epibatidine by fluorescence plate reader analysis2013Journal of natural products, Feb-22, Volume: 76, Issue:2
Alkaloids from Microcos paniculata with cytotoxic and nicotinic receptor antagonistic activities.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID145658Compound was evaluated for functional potency and efficacy at rat Nicotinic acetylcholine receptor in PC12 cells (ganglionic)1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Neuronal nicotinic acetylcholine receptors as targets for drug discovery.
AID159174Percent reversal against Plasmodium falciparum W2 at 1 uM DEEA2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Synthesis and effects on chloroquine susceptibility in Plasmodium falciparum of a series of new dihydroanthracene derivatives.
AID29338Dissociation constant (pKa)2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Synthesis and effects on chloroquine susceptibility in Plasmodium falciparum of a series of new dihydroanthracene derivatives.
AID1243914Antagonist activity at nAChR in Sprague-Dawley rat striatal slices assessed as inhibition of nicotine-induced [3H]-dopamine release2015European journal of medicinal chemistry, Aug-28, Volume: 101Bifunctional compounds targeting both D2 and non-α7 nACh receptors: design, synthesis and pharmacological characterization.
AID159876Accumulation coefficient of chloroquine at 1 uM-10 uM of DEEA against Plasmodium falciparum W22002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Synthesis and effects on chloroquine susceptibility in Plasmodium falciparum of a series of new dihydroanthracene derivatives.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID145358Compound was evaluated for functional potencies and efficacies at human muscle type Nicotinic acetylcholine receptor in TE671 cells1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Neuronal nicotinic acetylcholine receptors as targets for drug discovery.
AID761289Antagonist activity at human alpha4beta2 nAChR expressed in HEK-tsA201 cells assessed as inhibition of epibatidine-induced intracellular calcium level by fluorescence plate reader analysis2013Bioorganic & medicinal chemistry, Aug-01, Volume: 21, Issue:15
Discovery of benzamide analogs as negative allosteric modulators of human neuronal nicotinic receptors: pharmacophore modeling and structure-activity relationship studies.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID27587Partition coefficient (logP)2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Synthesis and effects on chloroquine susceptibility in Plasmodium falciparum of a series of new dihydroanthracene derivatives.
AID241633Inhibitory concentration against Nicotinic acetylcholine receptor alpha3-beta42005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.
AID244297Ki or IC50 concentration against Nicotinic acetylcholine receptor alpha4-beta42005Journal of medicinal chemistry, Jul-28, Volume: 48, Issue:15
Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations.
AID180080Hypotensive index (HI) measured as the area under the time-hypotensive response curve for 6-h period at 30 mg/kg, po1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
Studies on cardiovascular agents. 6. Synthesis and coronary vasodilating and antihypertensive activities of 1,2,4-triazolo[1,5-a]pyrimidines fused to heterocyclic systems.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID30377Maximum percent of enhancement of binding.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID311932Inhibition of ASM in human H4 cells assessed as residual activity at 10 uM2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID429982Antagonist activity at nAChR in Sprague-Dawley rat striatal slices assessed as inhibition of S(-)-nicotine-evoked [3H]dopamine overflow at 100 uM by liquid scintillation counting2009Bioorganic & medicinal chemistry, Jul-01, Volume: 17, Issue:13
QSAR study on maximal inhibition (Imax) of quaternary ammonium antagonists for S-(-)-nicotine-evoked dopamine release from dopaminergic nerve terminals in rat striatum.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID311934Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID158683In vitro inhibitory activity against multidrug-resistant Plasmodium falciparum W2 Indochina2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Synthesis and effects on chloroquine susceptibility in Plasmodium falciparum of a series of new dihydroanthracene derivatives.
AID27572Partition coefficient (logD7.0)2002Journal of medicinal chemistry, Jul-18, Volume: 45, Issue:15
Synthesis and effects on chloroquine susceptibility in Plasmodium falciparum of a series of new dihydroanthracene derivatives.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID736858Antagonist activity at human recombinant alpha3beta4 nAChR expressed in human HEKtsA201 cells assessed as inhibition of epibatidine-stimulated calcium accumulation at 10 uM pretreated and cotreated with epibatidine by fluorescence plate reader analysis2013Journal of natural products, Feb-22, Volume: 76, Issue:2
Alkaloids from Microcos paniculata with cytotoxic and nicotinic receptor antagonistic activities.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,963)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990630 (32.09)18.7374
1990's386 (19.66)18.2507
2000's523 (26.64)29.6817
2010's369 (18.80)24.3611
2020's55 (2.80)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.21 (24.57)
Research Supply Index7.63 (2.92)
Research Growth Index4.43 (4.65)
Search Engine Demand Index72.50 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials68 (3.41%)5.53%
Reviews41 (2.05%)6.00%
Case Studies2 (0.10%)4.05%
Observational0 (0.00%)0.25%
Other1,886 (94.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (19)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multi-Center, Double Blind, Randomized, Placebo-Controlled, Parallel Group, Flexible Dose Titration, Add-On Study of TC-5214 in the Treatment of MDD With Subjects Who Are Partial Responders or Non-Responders to Citalopram Therapy [NCT00692445]Phase 2574 participants (Actual)Interventional2008-06-30Completed
Pilot Study of Mecamylamine for Autonomic Dysreflexia Prophylaxis [NCT03914677]Phase 45 participants (Anticipated)Interventional2019-06-13Recruiting
A Multi-Center, Double Blind, Randomized, Placebo-Controlled, Parallel Group, Flexible Dose Titration, Add-On Study of Mecamylamine 5.0 to 10 mg, in the Treatment of Major Depressive Disorder With Subjects Who Are Partial or Non- Responders to Citalopram [NCT00593879]Phase 2450 participants (Actual)Interventional2005-02-28Completed
Treatment of Orthostatic Intolerance [NCT00262470]Phase 1/Phase 2150 participants (Anticipated)Interventional1997-04-30Active, not recruiting
The Nicotinic Cholinergic System and Cognitive Aging [NCT03408574]Phase 1104 participants (Actual)Interventional2016-10-01Completed
Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence [NCT00563797]Phase 321 participants (Actual)Interventional2007-08-31Completed
Neuronal Nicotinic Receptor Modulation in the Treatment of Autism: A Pilot Trial of Mecamylamine [NCT00773812]Phase 120 participants (Actual)Interventional2007-07-31Completed
Combinations of Pharmacologic Smoking Cessation Treatments [NCT00018187]Phase 10 participants Interventional1998-11-30Completed
Phase 2 Study of the Safety and Bioactivity of Topical Ocular Mecamylamine for the Treatment of Diabetic Macular Edema (DME) [NCT00536692]Phase 20 participants Interventional2007-09-30Completed
A Phase 2 Randomized, Double-Masked, Study to Evaluate the Safety and Preliminary Efficacy of ATG003 in Patients With Neovascular Age-Related Macular Degeneration (NV-AMD) Receiving Frequent Maintenance Intravitreal Anti-VEGF Antibody Therapy (Ranibizumab [NCT00607750]Phase 260 participants (Actual)Interventional2008-05-31Completed
Cholinergic Mechanisms of Attention in Aging [NCT04756232]Early Phase 180 participants (Anticipated)Interventional2022-04-21Recruiting
Nicotinic Modulation of the Default Network of Resting Brain Function [NCT01223404]21 participants (Actual)Interventional2010-10-31Completed
Attentional Mechanisms of Cognitive Compensation in Subjective Cognitive Decline [NCT06002477]Early Phase 180 participants (Anticipated)Interventional2024-03-01Not yet recruiting
Combined Pharmacologic/Behavioral Treatment for Smoking Cessation [NCT00018161]Phase 20 participants Interventional1997-01-31Completed
Treatment With Mecamylamine in Smoking and Non-smoking Alcohol Dependent Patients [NCT00342563]Phase 2136 participants (Actual)Interventional2004-05-31Completed
A Double-Blind,Randomized,Placebo-Controlled Trial of Mecamylamine Hydrochloride for the Treatment of SSRI-Refractory Major Depressive Disorder. [NCT00319319]Phase 260 participants Interventional2003-01-31Completed
Cognitive Effects of Mecamylamine and Varenicline in Schizophrenia [NCT00455650]89 participants (Actual)Interventional2007-03-31Completed
"A Phase II Randomized, Double-Masked, Study Comparing the Safety and Efficacy of ATG003 in Patients With Neovascular (Wet) Age-Related Macular Degeneration (NV-AMD)" [NCT00414206]Phase 2343 participants (Actual)Interventional2007-03-31Terminated(stopped due to Sponsor decision)
Cholinergic Correlates of Impaired Cognitive Ability in HIV-Associated Neurocognitive Disorders [NCT03244488]22 participants (Actual)Observational2015-12-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00342563 (4) [back to overview]Percent Heavy Drinking Days During Active Treatment Phase
NCT00342563 (4) [back to overview]Self-report Average Number of Cigarettes Per Day
NCT00342563 (4) [back to overview]Self-report Weekly Craving Via Obsessive Compulsive Drinking Scale (OCDS)
NCT00342563 (4) [back to overview]Self-report Weekly Smoking Craving
NCT00414206 (1) [back to overview]Proportion of Subjects Losing Fewer Than 15 ETDRS Letters of Visual Acuity at 48 Weeks Compared to Baseline.
NCT00455650 (4) [back to overview]Effects of Mecamylamine and Varenicline Compared With Placebo in Schizophrenia and Control Groups on Cognitive Interference as Assessed by The Three-card Stroop Task
NCT00455650 (4) [back to overview]Effects of Mecamylamine and Varenicline Compared With Placebo in Schizophrenia and Control Groups on Prolonged Attention as Assessed With the CPT-IP Hit Reaction Time Variability
NCT00455650 (4) [back to overview]Effects of Mecamylamine and Varenicline Compared With Placebo in Schizophrenia and Control Groups on Sustained Attention as Assessed by The N-back Task
NCT00455650 (4) [back to overview]Effects of Mecamylamine and Varenicline Compared With Placebo in Schizophrenia and Control Groups on Working Memory as Assessed by The Visual Spatial Working Memory (VSWM) Task
NCT00563797 (4) [back to overview]Depression - Measured Using the HAMD Total Score
NCT00563797 (4) [back to overview]Number of Drinking Days
NCT00563797 (4) [back to overview]Mean Percentage of Heavy Drinking Days by Smoking
NCT00563797 (4) [back to overview]Mean Percentage of Number of Drinking Days by Smoking Status
NCT01223404 (6) [back to overview]Default Network Activity
NCT01223404 (6) [back to overview]Subjective State
NCT01223404 (6) [back to overview]Diastolic Blood Pressure
NCT01223404 (6) [back to overview]Reaction Time
NCT01223404 (6) [back to overview]Signal Detection Performance
NCT01223404 (6) [back to overview]Systolic Blood Pressure

Percent Heavy Drinking Days During Active Treatment Phase

Data were calculated as number of heavy drinking days (heavy drinking days is defined as 5 drinks on a single occasion for men and 4 for women) average during 90 days of treatment. (NCT00342563)
Timeframe: 12 weeks

Interventiondays (Mean)
Mecamylamine- Smokers16.75
Mecamylamine- Non-Smoker24.28
Placebo-Smoker20.51
Placebo- Non-Smoker21.78

[back to top]

Self-report Average Number of Cigarettes Per Day

self-report from only the smoking population for cigarettes per day (NCT00342563)
Timeframe: 12 weeks

Interventioncigarettes (Mean)
Mecamylamine8.055
Placebo10.681

[back to top]

Self-report Weekly Craving Via Obsessive Compulsive Drinking Scale (OCDS)

The OCDS is a 14-item (rated 0-4), self-administered questionnaire for characterizing and quantifying the obsessive and compulsive cognitive aspects of craving and heavy (alcoholic) drinking, such as drinking-related thought, urges to drink, and the ability to resist those thoughts and urges. A higher total score indicates higher craving and ranges from 0-48. (NCT00342563)
Timeframe: 12 weeks

,
Interventionunits on a scale (Mean)
TotalNon-SmokersSmokers
Mecamylamine8.77210.5756.969
Placebo8.0328.3527.712

[back to top]

Self-report Weekly Smoking Craving

Questionnaire of smoking urges (QSU). It has 32 questions that range from 1 to 7, there are 8 questions per sub-scale. The total range is 32 to 224. Each sub-scale ranges from 8- 56, with a higher score indicating higher craving. (NCT00342563)
Timeframe: 12 weeks

,
Interventionunits on a scale (Mean)
Desire to SmokeAnticipation of a positive outcomeReliefIntention to smoke
Mecamylamine27.74128.70522.55731.108
Placebo28.04728.27324.03232.549

[back to top]

Proportion of Subjects Losing Fewer Than 15 ETDRS Letters of Visual Acuity at 48 Weeks Compared to Baseline.

(NCT00414206)
Timeframe: Baseline to Week 48

InterventionPercent of subjects (Number)
1% Mecamylamine88
0.3% Mecamylamine86
Placebo92

[back to top]

Effects of Mecamylamine and Varenicline Compared With Placebo in Schizophrenia and Control Groups on Cognitive Interference as Assessed by The Three-card Stroop Task

"In the 3-card Stroop Task, 3 cards were presented; the 1st contained color names printed in black ink, the 2nd contained colored patches of ink, the 3rd contained color names printed in incongruously colored ink. Participants were asked to read or name as many items as possible in 45 seconds for each condition. Individuals are asked to identify the color of the ink of a word. They may be distracted by the presence of a word that states another color (i.e. the word blue written in green ink would require the answer green).The interference score was calculated by dividing the color-word score by the color score. There is only one outcome measure time point because cognitive outcomes were analyzed using crossover analyses of covariance (ANCOVA) with drug (mecamylamine vs varenicline vs pbo) as a within subject factor, diagnosis (schizophrenia vs. control) as a between subject factor as well as study period and drug administration sequence as between subject crossover design factors" (NCT00455650)
Timeframe: Baseline (week 1), week 2, week 3, week 4 analyzed as a single time point

Interventionscore (Mean)
Schizophrenia: Mecamylamine50.2
Schizophrenia: Varenicline52.8
Schizophrenia: Placebo50.3
Control: Mecamylamine54.4
Control: Varenicline53.3
Control: Placebo53.5

[back to top]

Effects of Mecamylamine and Varenicline Compared With Placebo in Schizophrenia and Control Groups on Prolonged Attention as Assessed With the CPT-IP Hit Reaction Time Variability

The Continuous Performance Test-Identical Pairs, CPT-IP, Version 4.0 was developed and normed for use in people with schizophrenia and normal controls. This task estimates attention by requiring an individual to push a response key when two identical pairs of shapes or numbers are presented in sequence. Stimuli were presented with increasing cognitive load: 2-, 3-, and 4-digit targets. Outcome variables measured included correct hits, hit reaction time (HRT), errors of commission: false alarms and random errors, and the primary outcome, variability, or standard deviation, of hit reaction time, HRT-SD. There is only one outcome measure time point because cognitive outcomes were analyzed using crossover analyses of covariance (ANCOVA) with drug (mecamylamine vs. varenicline vs. placebo) as a within subject factor, diagnosis (schizophrenia vs. control) as a between subject factor, as well as study period and drug administration sequence as between subject crossover design factors. (NCT00455650)
Timeframe: Baseline (week 0), week 1, week 2 and week 3 as one time point (see outcome measure description)

Interventionms (Mean)
Schizophrenia: Mecamylamine141.6
Schizophrenia: Varenicline120.5
Schizophrenia: Placebo123.1
Control: Mecamylamine91.2
Control: Varenicline83.2
Control: Placebo87.8

[back to top]

Effects of Mecamylamine and Varenicline Compared With Placebo in Schizophrenia and Control Groups on Sustained Attention as Assessed by The N-back Task

"The N-back task with 1- and 2-back parametric conditions was used. During the task, a letter was displayed for 1,500 ms every 2 s with a 500 ms isi. Participants were asked to press the 1 key for letters that corresponded to the letter 1 back for the 1-back condition, the 2 key for the 2-back condition, and the 3 key for nontarget letters. Outcome variable presented is hit reaction time There is only one outcome measure time point because this outcome was analyzed using crossover analyses of covariance (ANCOVA) with drug (mecamylamine vs. varenicline vs. placebo) as a within subject factor, diagnosis (schizophrenia vs. control) as a between subject factor, as well as study period and drug administration sequence as between subject crossover design factors." (NCT00455650)
Timeframe: Baseline (week 1), week 2, week 3, week 4 analyzed as a single time point

Interventionms (Mean)
Schizophrenia: Mecamylamine909.2
Schizophrenia: Varenicline931.2
Schizophrenia: Placebo894.4
Control: Mecamylamine864.6
Control: Varenicline795.8
Control: Placebo827.5

[back to top]

Effects of Mecamylamine and Varenicline Compared With Placebo in Schizophrenia and Control Groups on Working Memory as Assessed by The Visual Spatial Working Memory (VSWM) Task

In the Visual spatial working memory (VSWM), participants were asked to place the cursor where the symbol appeared immediately after its display. For 16 additional trials, participants were asked to identify the symbol location after a 30-second delay. During the delay, participants were distracted by being asked to read aloud words appearing on the screen at 2-second intervals. The outcome of interest in this task were the average distance from the target for immediate and delayed recall There is only one outcome measure time frame because this outcome was analyzed using crossover analyses of covariance (ANCOVA) with drug (mecamylamine vs. varenicline vs. placebo) as a within subject factor, diagnosis (schizophrenia vs. control) as a between subject factor, as well as study period and drug administration sequence as between subject crossover design factors. (NCT00455650)
Timeframe: Baseline (week 1), week 2, week 3, week 4 analyzed as a single time point

InterventionDistance (in) (Mean)
Schizophrenia: Mecamylamine2.83
Schizophrenia: Varenicline2.72
Schizophrenia: Placebo2.87
Control: Mecamylamine2.29
Control: Varenicline2.28
Control: Placebo2.25

[back to top]

Depression - Measured Using the HAMD Total Score

"The Hamilton Depression Rating Scale (HAM-D) has proven useful for many years as a way of determining a patient's level of depression before, during, and after treatment. It should be administered by a clinician experienced in working with psychiatric patients.~Although the HAM-D form lists 21 items, the scoring is based on the first 17. It generally takes 15-20 minutes to complete the interview and score the results. The Scale ranges from 0 (normal) to >23 (Very Severe Depression)" (NCT00563797)
Timeframe: 12 weeks

Interventionunits on a scale (Mean)
Mecamylamine8.212
Placebo8.10

[back to top]

Number of Drinking Days

Measured with time line follow back measures (NCT00563797)
Timeframe: 25 weeks

Interventiondays (Mean)
Placebo17.6
Mecamylamine12.6

[back to top]

Mean Percentage of Heavy Drinking Days by Smoking

The two-way interaction between medication by smoking status to measure percentage of heavy drinking days measured by time line follow back survey. Data were calculated as number of heavy drinking days (heavy drinking days is defined as 5 drinks on a single occasion for men and 4 for women) over the number of days in the study for smokers and non smokers receiving either mecamylamine or placebo. (NCT00563797)
Timeframe: 25 weeks

,
Interventionpercentage of Heavy Drinking Days (Mean)
SmokersNon-Smokers
Mecamylamine15.143.57
Placebo1.6831.67

[back to top]

Mean Percentage of Number of Drinking Days by Smoking Status

Two-way interaction between smoking and medication for percentage of drinking days captured by time line follow back surveys. Data are calculated as number of drinking days over the number of days in the study for smokers and nonsmokers receiving either mecamylamine or placebo. (NCT00563797)
Timeframe: 25 weeks

,
InterventionPercentage of Drinking Days (Mean)
SmokersNon-Smokers
Mecamylamine21.3414.76
Placebo4.5748.81

[back to top]

Default Network Activity

Cognitive task-induced default network deactivation, measured by functional Magnetic Resonance Imaging. The default network was probed by five pre-defined ROIs per hemisphere. Task-induced deactivation was averaged across all ROIs. (NCT01223404)
Timeframe: 1 day

Interventionpercentage of task-induced signal change (Mean)
Intervention: Placebo-0.29
Intervention: Nicotine-0.24
Intervention: Mecamylamine-0.21

[back to top]

Subjective State

"End-of-session subjective state is measured by the Profile of Mood States (POMS). We utilize Total Mood Disturbance (TMD) as a summary measure, derived by adding the total scores on the five negative mood scales (tension, depression, anger, fatigue, confusion) and subtracting the score on the one positive mood scale (vigor). The theoretical range of the TMD scale is -32 to 228, with negative values indicating less mood disturbance, i.e., a more positive emotional state." (NCT01223404)
Timeframe: 1 day

Interventionunits on a scale (Mean)
Intervention: Placebo-6.7
Intervention: Nicotine-9.9
Intervention: Mecamylamine-5.8

[back to top]

Diastolic Blood Pressure

Diastolic blood pressure in mmHg. (NCT01223404)
Timeframe: Bi-hourly: prior to patch application, 2 hours, 4 hours, and 6 hours after, and after the MRI scan (~8 hours after patch application).

,,
InterventionmmHG (Mean)
Pre-patch2 hours post patch4 hours post patch6 hours post patchPost-scan
Intervention: Mecamylamine73.473.272.475.279.6
Intervention: Nicotine71.671.971.175.381.1
Intervention: Placebo74.473.473.775.881.3

[back to top]

Reaction Time

average reaction time on cognitive task performed in the MR scanner (NCT01223404)
Timeframe: 1 day

,,
Interventionms (Mean)
Attention task reaction timeWorking memory task reaction time
Intervention: Mecamylamine524573
Intervention: Nicotine492533
Intervention: Placebo512541

[back to top]

Signal Detection Performance

Signal detection on cognitive tasks performed in the MR scanner. For the attention task, this represents the percentage of trials in which the participant responded when a signal was presented. In the working memory task (N-back task), this represents the percentage of all target sequences to which the participant responded. (NCT01223404)
Timeframe: 1 day

,,
Interventionpercentage of all targets (Mean)
Attention task correct identificationsWorking memory task correct detections
Intervention: Mecamylamine85.288.6
Intervention: Nicotine93.895.5
Intervention: Placebo86.489.6

[back to top]

Systolic Blood Pressure

Systolic blood pressure (mmHg) (NCT01223404)
Timeframe: Bi-hourly: prior to patch application, 2 hours, 4 hours, and 6 hours after, and after the MRI scan (~8 hours after patch application)

,,
InterventionmmHG (Mean)
Pre-patch2 hours post patch4 hours post patch6 hours post patchPost-scan
Intervention: Mecamylamine119.3112.3114.4118.2121.5
Intervention: Nicotine120.9114.3119.1122.7127.4
Intervention: Placebo120.2116.1120.1120.3129.7

[back to top]